Clinical Trial Update: Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial investigating how UGT1A1 gene polymorphisms influence the toxicity and efficacy of irinotecan in patients with small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Irinotecan (Irinotecan)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Small Cell Carcinoma of Lung | Phase 2 | Status: UNKNOWN